Amarin Corp Plc (AMRN)

[ziploc_1]

The Amarin vs. Healthnet case points out a potential problem with the HW law...

Off label prescriptions are legal...However, where there are two or more indications for a drug in which one of the indications is patented, it is illegal to infringe on the patented indication...If there is evidence that an insurance company has knowledge that Vascepa is being used for the CVD indication and also the insurance company been using price or other means to induce infringement, there should be monetary penalties awarded to the drug company by the insurance company.

It can be clearly shown that Healthnet was guilty selling of generic Vascepa, which they knew was for the CVD indication from their own prior authorization requests and...in addition, they were selling it for a lower price than branded Vascepa.

If there is a settlement of the Amarin vs. Healthnet case, it should include monetary compensation.